Analyst Initiates Verastem With Neutral While 'Waiting For FDA Go-Ahead'

  • Mizuho initiated coverage on Verastem Inc VSTM with a Neutral rating and a price target of $2.
  • The analyst says it sees strong clinical rationale, but valuation expansion rests on the go-forward strategy in - Low-Grade Serous Ovarian Cancer (LGSOC) and clinical signals from the KRAS G12C programs.
  • The analyst writes that the shares are underpriced relative to the LGSOC market (~$1.5 billion) but waiting for clarity on accelerated approval and confirmatory trial, which could be a catalyst for valuation expansion.
  • Mizuho writes that VSTM shares are trading below what can be seen as the opportunity in LGSOC based on a multiple of peak revenue (less $100 million market cap versus peak revenue forecast of ~$800 million).
  • The analyst writes that the RAMP-201 interim data confirmed that the activity of avutometinib + defactinib looks competitive with other MEK inhibitors used in the setting.
  • Mizuho also writes that KRAS G12C combination programs offer upside as the market potential could be up to 2-3X LGSOC, but awaiting data - 2H23.
  • Price Action: VSTM shares are down 9.92% at $0.41 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CarePrice TargetInitiationAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!